| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Schizandrin C targets multiple pathways involved in inflammation, oxidative stress, and cancer. It exerts anti-inflammatory effects by upregulating phase II detoxifying/antioxidant enzymes, such as heme oxygenase-1 and NAD(P)H:quinone oxidoreductase, in microglia, thereby reducing neuroinflammation. The compound also exhibits anti-tumor activity by decreasing cancer cell viability and inducing cell cycle arrest at the G1 phase. Its antioxidant activity is mediated through the scavenging of reactive oxygen species and the enhancement of cellular antioxidant defenses.
|
|---|---|
| ln Vitro |
Schisandrin C (25-100 μM; 48 hours) down-regulates expression levels of Bcl-2, Bcl-xL and a concomitant degradation of poly(ADP-ribose) polymerase (PARP). Additionally, in U937 cells, it activates caspase-3 and -9[2].
Schisandrin C (25-100 μM; 48 hours) induces apoptosis in a dose-dependent manner. Additionally, U937 cells exhibit increased genomic DNA fragmentation[1]. Schisandrin C (25-100 μM; 72 hours) induces G1 arrest, down-regulates the expression of cyclin D1, cyclin E, cyclin-dependent kinase (Cdk) 4, and E2Fs, as well as inhibiting pRB and enhancing the Cdk inhibitor p21(WAF1/CIP1)[1]. In vitro, schizandrin C decreases the viability of U937 leukemia cells in a concentration-dependent manner and induces cell cycle arrest at the G1 phase. The compound also exerts anti-neuroinflammatory effects by upregulating phase II detoxifying/antioxidant enzymes in microglia. These in vitro studies confirm the anti-tumor, anti-inflammatory, and antioxidant activities of schizandrin C. |
| ln Vivo |
Schisandrin C (lateral ventricle injection (i.c.v. ); 15–150 g/kg; 5 days) lessens Aβ1-42-induced memory deficits in the Y-maze test. The hippocampus' neurons in the SCH-C (15 μg/kg)-treated group recovered to normal levels, and the SCH-C group (150 μg/kg) had a minimally neuroprotective effect on the Aβ1–42-induced group. In the brains of the Aβ1–42-induced amnesic mice, SCH-C (15 μg/kg) simultaneously reduces ChEtotal levels while increasing SOD and GSHPx activities and ratios[3].
In vivo, schizandrin C has been studied for its anti-inflammatory and antioxidant effects. The compound's ability to upregulate phase II detoxifying enzymes suggests potential benefits in reducing inflammation and oxidative stress in various tissues. Further in vivo studies would be required to fully characterize its therapeutic potential in animal models of inflammation, cancer, and neurodegenerative diseases. |
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cellular) assays for schizandrin C are not extensively documented. However, the compound's antioxidant activity can be assessed using cell-free assays such as DPPH radical scavenging or ABTS assays. The compound's ability to upregulate phase II detoxifying enzymes can be studied using cell-free transcription assays. Additionally, the compound's ability to inhibit specific enzymes involved in inflammation or cancer could be evaluated using biochemical assays.
|
| Cell Assay |
In vitro cellular assays for schizandrin C are performed using various cell types, including cancer cell lines (e.g., U937 leukemia cells) and microglial cells. Cells are treated with varying concentrations of schizandrin C, and cell viability is measured using MTT assays. Cell cycle distribution is analyzed by flow cytometry to assess G1 phase arrest. The expression of phase II detoxifying enzymes is measured by quantitative PCR or Western blotting. Inflammatory cytokine production is assessed by ELISA.
|
| Animal Protocol |
Aβ1-42-induced Alzheimer’s disease mice[3]
15-150 μg/kg Lateral ventricle injection (i.c.v.); 15-150 μg/kg; 5 days In vivo animal experiments for schizandrin C are not extensively documented in the available literature. However, the compound could be evaluated in animal models of inflammation, cancer, or neurodegenerative diseases. Standard protocols would involve administering schizandrin C to mice or rats via oral or intraperitoneal injection and assessing disease progression, inflammatory markers, oxidative stress, and tumor growth. The compound's anti-neuroinflammatory effects could be evaluated in models of neuroinflammation. |
| ADME/Pharmacokinetics |
Schizandrin C has a molecular weight of 384.42 g/mol and a molecular formula of C22H24O6. Detailed pharmacokinetic properties such as bioavailability, half-life, and tissue distribution have not been extensively reported in the available literature. As a lignan, schizandrin C may have moderate oral bioavailability and may undergo extensive metabolism. Further pharmacokinetic studies would be necessary to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Schizandrin C has been evaluated in preclinical studies and has been reported to be well-tolerated at effective doses. No significant toxicity has been reported in the available literature. As a natural product with a history of use in traditional medicine, schizandrin C is generally considered to have a favorable safety profile. However, comprehensive toxicology studies would be necessary to fully assess its safety for clinical development.
|
| References |
|
| Additional Infomation |
Schisandrin C has been reported to exist in Schisandra sphenanthera and Schisandra chinensis, and relevant data are available.
See also: Schisandrin C (note moved to). Schizandrin C is a dibenzocyclooctadiene lignan isolated from *Schisandra chinensis* (Turcz.) Baill. It exhibits anti-inflammatory, anti-tumor, and anti-oxidation activities. Schizandrin C decreases the viability of U937 cells and induces cell cycle arrest at the G1 phase. It also exerts anti-neuroinflammatory effects by upregulating phase II detoxifying/antioxidant enzymes in microglia. Schizandrin C is a research compound with potential applications in inflammation, cancer, and neurodegenerative diseases. |
| Molecular Formula |
C22H24O6
|
|---|---|
| Molecular Weight |
384.42
|
| Exact Mass |
384.157
|
| Elemental Analysis |
C, 68.74; H, 6.29; O, 24.97
|
| CAS # |
61301-33-5
|
| Related CAS # |
Schisandrin;7432-28-2
|
| PubChem CID |
119112
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
549.2±50.0 °C at 760 mmHg
|
| Melting Point |
122-123ºC
|
| Flash Point |
226.7±30.0 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
7.05
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
28
|
| Complexity |
509
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])([H])OC2=C1C([H])=C1C(=C2OC([H])([H])[H])C2=C(C3=C(C([H])=C2C([H])([H])[C@@]([H])(C([H])([H])[H])[C@@]([H])(C([H])([H])[H])C1([H])[H])OC([H])([H])O3)OC([H])([H])[H]
|
| InChi Key |
HTBWBWWADZJXID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H24O6/c1-11-5-13-7-15-19(27-9-25-15)21(23-3)17(13)18-14(6-12(11)2)8-16-20(22(18)24-4)28-10-26-16/h7-8,11-12H,5-6,9-10H2,1-4H3
|
| Chemical Name |
3,22-dimethoxy-12,13-dimethyl-5,7,18,20-tetraoxapentacyclo[13.7.0.02,10.04,8.017,21]docosa-1(22),2,4(8),9,15,17(21)-hexaene
|
| Synonyms |
Schizandrin-C; Schizandrin C
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 8.3~77 mg/mL (21.7~200.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6013 mL | 13.0066 mL | 26.0132 mL | |
| 5 mM | 0.5203 mL | 2.6013 mL | 5.2026 mL | |
| 10 mM | 0.2601 mL | 1.3007 mL | 2.6013 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
